- UBS and Truist Securities maintain cautious ratings (Neutral/Hold) on IBM, reflecting uncertainty in its near-term growth.
- Analysts question the timing of increased corporate spending on AI infrastructure and its impact on demand for IBM’s products and services.
- Despite potential in key offerings like Red Hat and watsonx Orchestrate, concerns about execution and customer demand timing persist.
IBM (NYSE: IBM) provides essential business software, mainframes, and consulting services. Its innovative offerings include Red Hat software and watsonx Orchestrate, which are crucial for helping companies manage complex AI-related work. UBS, a prominent financial institution, reiterates its Neutral rating on IBM, suggesting a recommendation to hold rather than buy or sell the stock. IBM traded at $232.47 when UBS published this rating on October 13, 2026.
Truist Securities also adopts a cautious perspective on the tech giant. It initiates coverage with a Hold rating and sets a price target of $240.00, reflecting an analyst’s estimate of where the stock could trade. Truist raises critical questions regarding the timeline for increased corporate spending on AI infrastructure to translate into stronger demand for IBM’s diverse products and services.
Analyst Arvind Ramnani identifies significant potential within IBM’s core offerings, including its robust mainframes, innovative watsonx Orchestrate platform, leading Red Hat software, and extensive consulting business. However, the precise timing of increased customer demand remains uncertain. Truist also expresses concerns about IBM’s ability to effectively execute its strategic plans, a point further emphasized by GuruFocus.
In a recent market snapshot, IBM shares traded at $231.64, marking an increase of $4.62, or 2.04%. During the trading day, shares fluctuated between $227.28 and $233.50, while the 52-week range spanned from $199.19 to $332.46. IBM’s current market value stands at approximately $218.24 billion, with 1.15 million shares traded.
